CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
BKM120drug
Likely dose
BKM120 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01629615
NCT01629615Phase 2Completed
CompareCT.gov

A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

SOLTI Breast Cancer Research Group·interventional·Posted Jun 27, 2012·Updated Oct 28, 2020

In Brief

A Phase 2 clinical trial evaluating BKM120 for Breast Cancer. Completed, enrolled 50 participants across 7 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the clinical activity of BKM120 in patients with metastatic triple-negative breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSpain, United States
CollaboratorsNovartis Pharmaceuticals, Dana-Farber Cancer Institute, Stand Up To Cancer

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 27, 2012
Enrollment StartJun 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.0 years ago

Interventions

BKM120drug

BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression